Contributor since: 2011
Company: The scott matusow show
Latest Articles
3 Biotechs With Upcoming Data At Conferences
Miragen Therapeutics May Provide Long-Term Alpha Within The RNA Space
4 Small-Cap Biotechs With Near-Term Trading Catalysts
MyoKardia Brings Hope To Hypertrophic Cardiomyopathy
GlycoMimetics: A New Angle On Tackling Chemo Resistance
Calithera Biosciences, Part 3: Arginase Inhibitor And Acquisition Target
Calithera Biosciences, Part 2 - TNBC And RCC Catalyst Value Drivers
Calithera Biosciences, Part 1 - Checkpoint Inhibition
The Results Of Negative Interest Rates: Short-Term Euphoria, Long-Term Problems
It's Not Greece Alone - Explaining And Defining Global Finance And The Current Systemic Risk
Fairway Group Likely To Beat On EPS, Potential Acquisition By Year End
MEI Pharma Is Undervalued By At Least Half And Will Recover, Here Is Why
Heavy Institutional Buying Is Occurring In MEI Pharma, Topline Data Due In Mid-March
3 Stocks That Should Move Significantly Higher Soon
Well-Known Activist Shareholder Pushing For Sale Of Identiv
Identiv Goes On The Record With NFC For Disney Infinity Toys: Star Wars Infinity Toys Likely Next
NFC Technology Integrated Into Smartphones Helps Pave The Road For Identiv
Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
Identiv's Post-Password Era Solutions Gaining Traction As Company Strengthens Financial Position
Identiv's Q2 Earnings Show Strong Growth - Acquisition Likely At Some Point
Identiv: An Internet Of Things Small-Cap Pick For Consideration
Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release
Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment
AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month
Activist Investor David Callan Has Been Accumulating Identiv Stock, Here's Why
Volcano Corp. Is Likely To Be Acquired Soon - Here Is Why
The IBB Likely To Move Higher Along With These Biotechs With Catalysts Upcoming
Progenics Pharma Poised For A Potential Price Increase Ahead Of June 11 Adcom
Orexigen's Weight Loss Drug Will Be Approved Soon And Will Lead Market - Here Is Why
Cytokinetics Binary Failure Provides Solid Buying Opportunity
Pozen Is Overvalued, More So Now After Recent FDA Rejection - Here Is Why
High-Risk Small Cap Biotech Keryx Pharma Has Become Overvalued